<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406444</url>
  </required_header>
  <id_info>
    <org_study_id>2R01DK052625</org_study_id>
    <nct_id>NCT01406444</nct_id>
  </id_info>
  <brief_title>IGF-1 and Bone Loss in Women With Anorexia Nervosa</brief_title>
  <official_title>IGF-1 and Bone Loss in Women With Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in
      bone density). A significant decrease in bone density is called osteopenia or osteoporosis.
      Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the
      bones. It is not known what causes the bones to thin in anorexia nervosa. Women who have this
      condition often have thin or weak bones that are more likely to break. They also have very
      low levels of a chemical called IGF-1 in their body. This chemical is very important for
      increasing bone growth in puberty and for maintaining healthy adult bones. The investigators
      would like to find out if giving rhIGF-1 followed by risedronate or risedronate alone can
      lead to an increase in bone formation, bone density, and bone strength in women with anorexia
      nervosa.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>12 Months</time_frame>
    <description>Sequential therapy with physiologic rhIGF-1 followed by a bisphosphonate will increase bone mineral density in women with AN more than a bisphosphonate alone or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Microarchitecture and strength</measure>
    <time_frame>12 Months</time_frame>
    <description>A significant improvement in bone microarchitecture and strength at the spine, ultradistal radius and tibia over a 12 month period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anorexia Nervosa</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>rhIGF-1 followed by Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sequential therapy with rhIGF-1 for 6 months followed by 6 months of risedronate 35mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risedronate 35mg for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhIGF-1</intervention_name>
    <description>Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.</description>
    <arm_group_label>rhIGF-1 followed by Risedronate</arm_group_label>
    <other_name>Increlex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>Risedronate 35mg PO one time weekly</description>
    <arm_group_label>rhIGF-1 followed by Risedronate</arm_group_label>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>Actonel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-45 years

          -  AN defined by DSM-IV diagnostic criteria, including weight less than 85% of ideal body
             weight (restricting or binge/purge type, BMI 15-17.5) OR meet criteria for
             sub-threshold AN, i.e., all DSM-IV criteria except that patients can have a BMI of
             &lt;18.5 kg/m2 with or without amenorrhea

          -  Oral contraceptive use prior to enrollment

          -  BMD T score &lt; -1.0

          -  Normal FSH and TSH or free T4

          -  Normal serum 25-OH vitamin D (&gt;20 ng/mL) and calcium levels

          -  Ongoing care from a primary care provider

          -  Agree to use barrier contraception

        Exclusion Criteria:

          -  Any subject with contraindications to risedronate

          -  Any subject with binge-purge subtype of anorexia nervosa who vomits regularly as their
             form of purging (vs. those who use laxatives or diuretics) and who have significant
             periodontal disease, tooth erosion or an invasive dental or periodontal procedure
             within the previous three months.

          -  Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's
             or renal failure

          -  Any medication known to affect bone metabolism within 3 months of the study, excluding
             oral contraceptives. Bisphosphonates must have been discontinued for at least one year
             before participation

          -  Serum potassium &lt;3.0 meq/L

          -  Serum ALT &gt;3 times upper limit of normal

          -  eGFR of less than 30 ml/min

          -  Pregnant and/or breastfeeding

          -  Diabetes mellitus

          -  Active substance abuse, including alcohol

          -  History of malignancy

          -  Atraumatic fracture within the prior year
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Klibanski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erinne Meenaghan, NP</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Miller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erinne Meenaghan, NP</last_name>
    <phone>617-724-7393</phone>
    <email>emeenaghan@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Miller, MD</last_name>
    <phone>617-726-3870</phone>
    <email>KKMiller@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Klibanski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Miller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erinne Meenaghan, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Anne Klibanski, MD</investigator_full_name>
    <investigator_title>Chief, Neuroendocrine Unit</investigator_title>
  </responsible_party>
  <keyword>Anorexia Nervosa</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Bone density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

